+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

HT-SPOTi: A Rapid Drug Susceptibility Test (DST) to Evaluate Antibiotic Resistance Profiles and Novel Chemicals for Anti-Infective Drug Discovery



HT-SPOTi: A Rapid Drug Susceptibility Test (DST) to Evaluate Antibiotic Resistance Profiles and Novel Chemicals for Anti-Infective Drug Discovery



Current Protocols in Microbiology 40: 17.8.1-12



Antibiotic resistance is one of the major threats to global health and well-being. The past decade has seen an alarming rise in the evolution and spread of drug-resistant strains of pathogenic microbes. The emergence of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis and antimicrobial resistance among the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) as well as fungal pathogens (such as certain species of Candida, Aspergillus, Cryptococcus, and Trichophyton) poses a significant 21st century scientific challenge. With an extremely limited arsenal of efficacious antibiotics, techniques that can (a) identify novel antimicrobials and (b) detect antimicrobial resistance are becoming increasingly important. In this article, we illustrate the HT-SPOTi, an assay that is principally based on the growth of an organism on agar medium containing a range of different concentrations of drugs or inhibitors. The simple methodology makes this assay ideal for evaluating novel antimicrobial compounds as well as profiling an organism's antibiotic resistance profile.

(PDF emailed within 0-6 h: $19.90)

Accession: 057963913

Download citation: RISBibTeXText

PMID: 26855282

DOI: 10.1002/9780471729259.mc1708s40


Related references

Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metabolism and Drug Interactions 21(3-4): 163-185, 2006

A toxicology study to evaluate the embryotoxicity of metformin compared with the hypoglycemic drugs, the anticancer drug, the anti-epileptic drug, the antibiotic, and the cyclo-oxygenase (COX)-2 inhibitor. Journal of Diabetes 7(6): 839-849, 2016

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Antibiotic-Associated Colitis. Clinical Infectious Diseases 15: S263-S267, 1992

Steps to address anti-microbial drug resistance in today's drug discovery. Expert Opinion on Drug Discovery 2018: 1-4, 2018

Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development. Infectious Disorders Drug Targets 13(5): 330-336, 2014

Macrolide Hybrid Compounds: Drug Discovery Opportunities in Anti- Infective and Anti-inflammatory Area. Current Topics in Medicinal Chemistry 17(8): 919-940, 2016

Making space for anti-infective drug discovery. Cell Host and Microbe 9(5): 343-348, 2011

Genomics in anti-infective drug discovery--getting to endgame. Current Pharmaceutical Design 8(13): 1099-1118, 2002

Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali. Clinical Microbiology and Infection 23(6): 408.E1-408.E6, 2017

Microscopic Observation Drug Susceptibility Assay for Rapid Diagnosis of Lymph Node Tuberculosis and Detection of Drug Resistance. Journal of Clinical Microbiology 54(1): 185-189, 2016

Traditional Chinese herbs as chemical resource library for drug discovery of anti-infective and anti-inflammatory. Journal of Ethnopharmacology 155(1): 589-598, 2015

New approaches for anti-infective drug discovery: antibiotics, vaccines and beyond. Current Drug Targets. Infectious Disorders 3(1): 66-75, 2003

Evaluation of GenoType® MTBDRplus assay for rapid detection of drug susceptibility testing of multi-drug resistance tuberculosis in Northern India. Indian Journal of Pathology and Microbiology 56(2): 139-143, 2014

An in silico structure-based approach to anti-infective drug discovery. Parasitology 141(1): 17-27, 2014

Discovery of the first macrolide antibiotic binding protein in Mycobacterium tuberculosis: a new antibiotic resistance drug target. Protein and Cell 9(11): 971-975, 2018